Login to Your Account

Other news to note

Friday, January 12, 2018

Xortx Pharma Corp., of Calgary, Alberta, said it completed a reverse merger with Apac Resources Inc., with the resulting company, Xortx Therapeutics Inc., to focus on developing therapies for rare orphan disease indications such as polycystic kidney disease, and the treatment of health consequences caused by chronic high serum uric acid, including type 2 diabetic nephropathy, cardiovascular disease and diabetes.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription